NCT04981899 2023-04-12
NICE-40
St. Petersburg State Pavlov Medical University
Phase 1/2 Unknown
Clinical Trials
6 trialsNCT05772624 2023-03-16
Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Unknown
NCT05660993 2022-12-21
Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma
National Research Center for Hematology, Russia
Phase 2 Unknown
NCT05385263 2022-05-26
Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion
Tel-Aviv Sourasky Medical Center
Phase 2 Unknown
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT03569696 2019-04-23
NivoM
Sheba Medical Center
Phase 2 Unknown